Novo Nordisk‘s (NYSE: NVO) place as a scorching healthcare inventory received a lift from an analyst because the buying and selling week got here to a detailed. On a big value goal enhance, the Danish pharmaceutical firm’s share value closed the day nearly 4% increased. That was greater than ok to outpace the bellwether S&P 500 index, which rose by a comparatively gentle 0.8%.
An analyst raised his value goal at a double-digit fee
The analyst giving Novo Nordisk that good shot within the arm was Morgan Stanley‘s Mark Purcell. Effectively earlier than market open that day, Purcell lifted his value goal on the corporate’s shares by 16% to 930 Danish kroner ($135) from his earlier 800 kroner ($116). Like quite a few different prognosticators, he is a Novo Nordisk bull; he maintained his strong obese (learn: purchase) suggestion on the shares as he lifted his value goal.
It is not arduous to be optimistic about Novo Nordisk nowadays. The European pharmaceutical firm has an absolute smash-hit product on its arms with Wegovy, the weight problems drug that has discovered fairly a receptive affected person base within the U.S. (with its excessive proportion of obese residents).
Weight reduction has been an incredible achieve for Novo Nordisk in latest instances. This was starkly illustrated by the corporate’s full-year 2023 efficiency through which it grew gross sales a sturdy 36%. Of its 4 remedy areas, weight problems care was by far the most well liked grower, with its income rising 154% over the 2022 tally.
Competitors is on the way in which, nonetheless
The pharmaceutical sector is full of strong, well-capitalized firms, and a few are already coming for Novo Nordisk’s lunch. Eli Lilly‘s Mounjaro diabetes drug has gained U.S. Meals and Drug Administration (FDA) approval for weight problems remedy and is hitting the market underneath the jazzy model title Zepbound. In the meantime, Viking Therapeutics reported very promising outcomes from a section 2 scientific trial of its personal weight-loss drug candidate.
So, though Novo Nordisk remains to be the pacesetter on this recreation, buyers must maintain a cautious eye on the strikes of different entrants.
Do you have to make investments $1,000 in Novo Nordisk proper now?
Before you purchase inventory in Novo Nordisk, think about this:
The Motley Idiot Inventory Advisor analyst staff simply recognized what they consider are the 10 greatest shares for buyers to purchase now… and Novo Nordisk wasn’t one among them. The ten shares that made the reduce might produce monster returns within the coming years.
Inventory Advisor gives buyers with an easy-to-follow blueprint for fulfillment, together with steering on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than tripled the return of S&P 500 since 2002*.
*Inventory Advisor returns as of February 26, 2024
Eric Volkman has no place in any of the shares talked about. The Motley Idiot recommends Novo Nordisk. The Motley Idiot has a disclosure coverage.
Why Novo Nordisk Inventory Topped the Market In the present day was initially revealed by The Motley Idiot
